Delta-Fly Pharma

Executive Summary

Delta-Fly Pharma is a Japanese preclinical biotech specializing in next-generation drug delivery systems for oncology. Founded in 2020 and headquartered in Tokyo, the company leverages its proprietary DFP technology platform to enhance the efficacy and reduce side effects of anti-cancer drugs. Its lead program targets acute myeloid leukemia (AML), a hematologic malignancy with high unmet need, by improving the delivery of therapeutics directly to cancer cells. The company operates in the highly competitive oncology space but differentiates itself through a focus on advanced delivery mechanisms that could broaden the therapeutic window of existing and novel agents. As a private, preclinical-stage company, Delta-Fly Pharma faces significant development risk but offers potential upside if its DFP platform demonstrates differentiation in early studies. The AML program is expected to advance toward IND-enabling studies, and the platform may be leveraged for other solid tumors. Given the early stage, conviction is moderate, with key value inflection points tied to regulatory progress and preclinical data. The company's success will depend on execution of its development plan and ability to attract partnerships for further clinical advancement.

Upcoming Catalysts (preview)

• Q1 2027IND filing for lead AML program60% success
• Q3 2026Preclinical proof-of-concept data for DFP platform in solid tumors70% success
• H2 2026Partnership or licensing deal for DFP technology30% success